Akumina Named A Strong Performer in 2020 Intranet Platforms Evaluation by Leading Independent Research Firm
16.6.2020 18:47:00 EEST | Business Wire | Press release
Akumina, the leading global Employee Experience Platform (EXP) software provider and one of INC Magazine’s Top 200 fastest growing companies in North America, announced today that they’ve been named a Strong Performer by Forrester Research, Inc. in The Forrester Wave™: Intranet Platforms, Q2 2020 report.
Akumina received the highest scores possible in seven criteria, including Personalization, Integration & Interoperability, and Design Tools.
Akumina’s inclusion in this evaluation is important especially to large enterprises working to improve employee experience, as it shows the strength and innovation of the organization’s technology. Many large enterprise customers like Banner Health, ING, and GlaxoSmithKline have already successfully partnered with Akumina.
“The Forrester Wave report is a well-respected resource for global organizations looking to partner with a software vendor ranked favorably in product quality, overall strategy, industry expertise and proven customer success,” says Akumina President and Co-Founder, David Maffei. “We feel being named a Strong Performer in the Forrester Wave reinforces our belief in the power of our platform and our strategy. It’s humbling and exciting to earn such a high honor from a respected independent third party like Forrester.”
Customer perspective is also considered an important part of the evaluation, which states, “Reference customers attest to the power of Akumina’s design tools, ease of content creation/editing, and ability to personalize communication.”
Akumina is laser focused on transforming the employee experience for medium and large enterprises around the globe with north of 4.5 million daily active users and customers using the platform in 80 countries and in over 60 different languages.
“Our intranet has become a unified, personalized platform connecting our employees to tools, information and each other. It empowers employees to take action, find solutions and share knowledge and experiences,” says Keith Kratochvil, Enterprise Architect at long-time Akumina customer the Principal Financial Group.
Akumina has also received recognition from organizations like ClearBox Consulting, The Tech Tribune, and CIO Review and has partnered with industry leaders such as Avanade, the leading digital innovator in the Microsoft ecosystem.
“Avanade is extremely excited with Akumina’s inclusion and placement in the 2020 Forrester Wave Report for Intranet Platforms. We took a strategic position in Akumina to help our clients to drive adoption and effective use of Digital Workplace tools at enterprise scale and we’ve seen our enterprise clients achieve strong results pivoting to a Digital-Hub-on-Akumina approach to reduce day-to-day friction in their organizations,” said Florin Rotar, Executive, Global Modern Workplace Lead at Avanade & Accenture Microsoft Business Group.
To learn more about Akumina, or to download a copy of the Forrester Wave™ Report on Intranet Platforms, please visit www.akumina.com.
About Akumina
Akumina is the employee experience platform that empowers global enterprises to quickly create personalized digital experiences that help every employee in every role work smarter, not harder. By offering a customizable, brandable and multilingual platform that seamlessly integrates with leading enterprise cloud applications, Akumina delivers a contextual, collaborative, and engaging workplace experience to every user on any device. Akumina’s customers include ING, Principal Financial Group, Whole Foods Market, GlaxoSmithKline, Vodafone, the Boston Red Sox and the Department of Defense. To learn more visit www.akumina.com or follow us on LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005822/en/
Contact information
Michael Scott
VP of Marketing
Michael.Scott@akumina.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom